Aurora Spine Stock Price, News & Analysis

Aurora Spine Corporation (OTCQB: ASAPF), a leader in spine and interventional spine technology, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the virtual event.

Interested parties can access the webcast through the conference homepage or directly via the provided link. The presentation will be available for replay after the event. Investors wishing to schedule one-on-one meetings with management can do so by contacting Lytham Partners or registering through the conference website.

Aurora Spine Corporation (OTCQB: ASAPF) has announced the schedule for its first quarter fiscal 2025 financial results release. The company will file results with SEDAR on Wednesday, May 21, 2025 after market hours, followed by a press release on May 22, 2025 before market trading.

A conference call for investors will be held on Thursday, May 22, 2025, at 11:00 a.m. ET / 8:00 a.m. PT. Investors can join via phone at (844) 861-5497 or (412) 317-5794, or through a live webcast. A replay will be available until May 29, 2025, and the webcast recording will be accessible for 90 days.

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced it will release its fourth quarter and fiscal year 2024 financial results on Monday, April 28, 2025, after market hours. The company will host a conference call for investors on Tuesday, April 29, 2025, at 11:00 am ET/8:00am PT.

The company also disclosed a clarification regarding its stock option plan, noting that previous management information circulars for 2023 and 2024 shareholder meetings referenced an outdated version. The correct version, approved by the board in 2022, will be included in the upcoming annual general meeting materials.

Aurora Spine (OTCQB: ASAPF) announced that James Snow, a board member since 2012, has resigned from the Board of Directors to become the company's Regulatory Affairs and Quality Assurance Manager. Snow, who brings over 20 years of medical device experience in regulatory affairs and quality, will focus on ensuring compliance requirements are met and exceeded.

The transition marks Snow's shift from a strategic to an operational role, where he will leverage his industry expertise to drive quality and compliance across Aurora's expanding innovative product portfolio. The company, which specializes in designing and manufacturing innovative medical devices for spinal surgery outcomes, views this internal movement as strengthening their operational capabilities.

Aurora Spine (OTCQB: ASAPF) announced the publication of a biomechanical study in Neurospine journal, demonstrating the superior performance of their SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional techniques.

The study revealed that the posterior interposition technique used by SiLO TFX™ achieved a 42% ± 8% reduction in joint motion, significantly outperforming the 14% ± 4% reduction observed with conventional posterolateral transosseous techniques. The system maintained stable bone-implant interface across all specimens, while traditional methods showed migration in 20%-50% of cases.

Key advantages of the SiLO TFX™ system include:

• Less bone volume removal
• Larger surface area for fusion
• Enhanced stability through transfixing design
• Minimally invasive approach

Aurora Spine (OTCQB: ASAPF) has received FDA 510(k) clearance for its new AERO™ Facet Fusion System, a minimally invasive solution for facet joint-related pain and instability. The patent-pending device is cleared for spinal levels C2 to S1 and can be used as a standalone procedure or alongside larger spinal fusion surgeries.

The system is specifically designed for patients with mechanical back pain, minor instability, or degenerative joint disease who haven't responded to conservative therapies. Initial surgeries with AERO are scheduled to begin in late Q3 2025, accompanied by a clinical study to validate outcomes and long-term benefits.

The AERO system features intuitive instrumentation and implant technology aimed at promoting bone fusion while minimizing soft tissue disruption, aligning with the company's focus on patient-first, surgeon-friendly innovations.

Aurora Spine (OTCQB: ASAPF) has announced its participation in the 2025 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting from March 10-14, 2025, at the San Diego Convention Center – Booth #1847.

At the world's largest gathering of orthopedic professionals, Aurora Spine will showcase its innovative product line, including:

• DEXA-C™: A cervical cage for ACDF procedures featuring patented DEXA Technology™ that matches implant density to patient's bone density
• SiLO TFX™ SI Fusion System: A patented, minimally invasive system for sacroiliac joint fusion, designed to treat conditions like sacroiliac joint disruptions and degenerative sacroiliitis
• ZIP product line: Offering Screwless Procedure for MIS Interspinous fusion

CEO Trent Northcutt emphasized the meeting's importance for introducing doctors to new technologies, particularly highlighting DEXA-C's unique bone density matching capability.

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced the completion of patient enrollment in its groundbreaking REFINE study, evaluating the ZIP™ Interspinous Fixation device for back pain treatment. This first-of-its-kind prospective, multi-center, multi-specialty clinical trial aims to assess the safety and efficacy of lumbar interlaminar fusion devices.

The study results will be published with one-year data, followed by a two-year cohort publication, and will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025. The REFINE study uniquely combines expertise from neurosurgeons, orthopedic surgeons, and interventional pain physicians to evaluate the ZIP™ MIS Interspinous Fusion System, offering a minimally invasive alternative to traditional spinal surgery for patients with lumbar spinal stenosis and degenerative disc disease.